HLA-DR-/JJ
,/,
CD33+/JJ
,/,
CD56+/JJ
,/,
CD16-/JJ
myeloid/natural/JJ
killer/NN
cell/NN
acute/JJ
leukemia/NN
:/:
a/DT
previously/RB
unrecognized/JJ
form/NN
of/IN
acute/JJ
leukemia/NN
potentially/RB
misdiagnosed/JJ
as/IN
French-American-British/JJ
acute/JJ
myeloid/JJ
leukemia-M3/NN
[/(
see/VB
comments/NNS
]/)

We/PRP
have/VBP
identified/VBN
and/CC
characterized/VBN
a/DT
previously/RB
unrecognized/JJ
form/NN
of/IN
acute/JJ
leukemia/NN
that/WDT
shares/VBZ
features/NNS
of/IN
both/CC
myeloid/JJ
and/CC
natural/JJ
killer/NN
(/(
NK/NN
)/)
cells/NNS
./.
=====
From/IN
a/DT
consecutive/JJ
series/NN
of/IN
350/CD
cases/NNS
of/IN
adult/JJ
de/FW
novo/FW
acute/JJ
myeloid/JJ
leukemia/NN
(/(
AML/NN
)/)
,/,
we/PRP
identified/VBD
20/CD
cases/NNS
(/(
6/CD
%/NN
)/)
with/IN
a/DT
unique/JJ
immunophenotype/NN
:/:
CD33+/JJ
,/,
CD56+/JJ
,/,
CD11a+/JJ
,/,
CD13lo/JJ
,/,
CD15lo/JJ
,/,
CD34+/-/JJ
,/,
HLA-DR-/JJ
,/,
CD16-/JJ
./.
=====
Multicolor/JJ
flow/NN
cytometric/JJ
assays/NNS
confirmed/VBD
the/DT
coexpression/NN
of/IN
myeloid/JJ
(/(
CD33/NN
,/,
CD13/NN
,/,
CD15/NN
)/)
and/CC
NK/NN
cell-associated/JJ
(/(
CD56/NN
)/)
antigens/NNS
in/IN
each/DT
case/NN
,/,
whereas/IN
reverse/NN
transcription/NN
polymerase/NN
chain/NN
reaction/NN
(/(
RT-PCR/NN
)/)
assays/NNS
confirmed/VBD
the/DT
identity/NN
of/IN
CD56/NN
(/(
neural/JJ
cell/NN
adhesion/NN
molecule/NN
)/)
in/IN
leukemic/JJ
blasts/NNS
./.
=====
Although/IN
two/CD
cases/NNS
expressed/VBD
CD4/NN
,/,
no/DT
case/NN
expressed/VBD
CD2/NN
,/,
CD3/NN
,/,
or/CC
CD8/NN
and/CC
no/DT
case/NN
showed/VBD
clonal/JJ
rearrangement/NN
of/IN
genes/NNS
encoding/VBG
the/DT
T-cell/NN
receptor/NN
(/(
TCR/NN
beta/NN
,/,
gamma/NN
,/,
delta/NN
)/)
./.
=====
Leukemic/JJ
blasts/NNS
in/IN
the/DT
majority/NN
of/IN
cases/NNS
shared/VBD
unique/JJ
morphologic/JJ
features/NNS
(/(
deeply/RB
invaginated/JJ
nuclear/JJ
membranes/NNS
,/,
scant/JJ
cytoplasm/NN
with/IN
fine/JJ
azurophilic/JJ
granularity/NN
,/,
and/CC
finely/RB
granular/JJ
Sudan/NN
black/JJ
B/NN
and/CC
myeloperoxidase/NN
cytochemical/JJ
reactivity/NN
)/)
that/WDT
were/VBD
remarkably/RB
similar/JJ
to/TO
those/DT
of/IN
acute/JJ
promyelocytic/JJ
leukemia/NN
(/(
APL/NN
)/)
;/:
particularly/RB
the/DT
microgranular/JJ
variant/NN
(/(
FAB/NN
AML-M3v/NN
)/)
./.
=====
However/RB
,/,
all/DT
20/CD
cases/NNS
lacked/VBD
the/DT
t(15;17)/NN
and/CC
17/CD
cases/NNS
tested/VBN
lacked/VBD
the/DT
promyelocytic/retinoic/JJ
acid/NN
receptor/NN
alpha/NN
(/(
RAR/NN
alpha/NN
)/)
fusion/NN
transcript/NN
in/IN
RT-PCR/NN
assays/NNS
;/:
12/CD
cases/NNS
had/VBD
46,XX/NN
or/CC
46,XY/NN
karyotypes/NNS
,/,
whereas/IN
2/CD
cases/NNS
had/VBD
abnormalities/NNS
of/IN
chromosome/NN
17q/NN
:/:
1/CD
with/IN
del(17)(q25)/NN
and/CC
the/DT
other/JJ
with/IN
t(11;17)(q23;q21)/NN
and/CC
the/DT
promyelocytic/JJ
leukemia/NN
zinc/NN
finger/RAR/NN
alpha/NN
fusion/NN
transcript/NN
./.
=====
All/DT
cases/NNS
tested/VBN
(/(
6/20/CD
)/)
,/,
including/VBG
the/DT
case/NN
with/IN
t(11;17)/NN
,/,
failed/VBD
to/TO
differentiate/VB
in/FW
vitro/FW
in/IN
response/NN
to/TO
all-trans/JJ
retinoic/JJ
acid/NN
(/(
ATRA/NN
)/)
,/,
suggesting/VBG
that/IN
these/DT
cases/NNS
may/MD
account/VB
for/IN
some/DT
APLs/NNS
that/WDT
have/VBP
not/RB
shown/VBN
a/DT
clinical/JJ
response/NN
to/TO
ATRA/NN
./.
=====
Four/CD
of/IN
6/CD
cases/NNS
tested/VBN
showed/VBD
functional/JJ
NK/NN
cell-mediated/JJ
cytotoxicity/NN
,/,
suggesting/VBG
a/DT
relationship/NN
between/IN
these/DT
unique/JJ
CD33+/JJ
,/,
CD56+/JJ
,/,
CD16-/JJ
acute/JJ
leukemias/NNS
and/CC
normal/JJ
CD56+/JJ
,/,
CD16-/JJ
NK/NN
precursor/NN
cells/NNS
./.
=====
Using/VBG
a/DT
combination/NN
of/IN
panning/NN
and/CC
multiparameter/NN
flow/NN
cytometric/JJ
sorting/NN
,/,
we/PRP
identified/VBD
a/DT
normal/JJ
CD56+/JJ
,/,
CD33+/JJ
,/,
CD16-/JJ
counterpart/NN
cell/NN
at/IN
a/DT
frequency/NN
of/IN
1/CD
%/NN
to/TO
2/CD
%/NN
in/IN
the/DT
peripheral/JJ
blood/NN
of/IN
healthy/JJ
individuals/NNS
./.
=====
Our/PRP$
studies/NNS
suggest/VBP
that/IN
this/DT
form/NN
of/IN
acute/JJ
leukemia/NN
may/MD
arise/VB
from/IN
transformation/NN
of/IN
a/DT
precursor/NN
cell/NN
common/JJ
to/TO
both/CC
the/DT
myeloid/JJ
and/CC
NK/NN
cell/NN
lineages/NNS
;/:
thus/RB
we/PRP
propose/VBP
the/DT
designation/NN
myeloid/NK/JJ
acute/JJ
leukemia/NN
./.
=====
Recognition/NN
of/IN
this/DT
new/JJ
leukemic/JJ
entity/NN
will/MD
be/VB
important/JJ
in/IN
distinguishing/VBG
these/DT
ATRA-nonresponsive/JJ
cases/NNS
from/IN
ATRA-responsive/JJ
true/JJ
APL/NN
./.